Extended Data Fig. 3: In vitro expression of SARS-CoV-2 spike mRNA on the cell surface.
From: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
a–d, 293T cells were transfected in duplicate with mRNA expressing SARS-CoV-2 wild-type spike (white bars, black lines) or S-2P (red), stained with ACE2 (a, c) or CR3022 (b, d), and evaluated by flow cytometry 24 post-transfection. Mock-transfected (PBS) cells served as a control (grey). (a, b) Data are presented as mean.
